{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:55:24Z","timestamp":1771592124385,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2005,5,31]],"date-time":"2005-05-31T00:00:00Z","timestamp":1117497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2005,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Histology after intensive induction chemotherapy is expected to become a beacon indicating when and how extensively radical surgery and lymph node dissection should be performed in advanced neuroblastoma. A thorough histologic review of surgical specimens was undertaken.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>All specimens from 34 patients who were pretreated intensively (\u22653 cycles) with recent chemotherapy were reviewed. Thirty patients were &gt;12 months of age with stage 3\/4 disease, and 4 were &lt;12 months of age but with <jats:italic>MYCN<\/jats:italic>\u2010amplified stage 4 diseases. After 3 to 7 cycles (mean, 4.3 cycles) of induction chemotherapy, patients underwent radical surgery of the primary tumor and lymph nodes in all retroperitoneal sections. A single pathologist reviewed all of the specimens, and histologic chemotherapeutic effects were graded as: (+++), &lt;1% viable tumor; (++), 1%\u201310% viable tumor; (+), 11%\u201350% viable tumor; (\u00b1), 51%\u201390% viable tumor; and (\u2212), &gt;91% viable tumor.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Grade (+++) effects were observed in 56% of patients treated with the new regimens, whereas grade (+++) was seen in only 20% treated with regimens before 1991. Operation time and blood loss were 7 hr and 6 min (<jats:italic>P<\/jats:italic>\u2009=\u20090.087) and 646 ml (<jats:italic>P<\/jats:italic>\u2009=\u20090.064), respectively, in patients with &gt;5 cycles (mean, 5.3 cycles) of chemotherapy, while they were 7 hr and 50 min and 1,168 ml, respectively, in those with approximately 3 cycles (mean, 3.2 cycles). Histologically, metastases were found in the contralateral nodes beyond the aorta in 92% of those whose tumor originated on the left, and in 80% of those with tumors occurring on the right.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Five cycles of induction chemotherapy did not improve histologic chemotherapeutic effects, but helped to facilitate a shorter operation time and less blood loss than 3 cycles of chemotherapy. Surgery after 5 cycles of <jats:sub>98<\/jats:sub>A<jats:sub>3<\/jats:sub> also appears to be easier to perform than that after 3 cycles of A<jats:sub>1<\/jats:sub>\/new A<jats:sub>1<\/jats:sub>. Only 14% of the children treated before 1985 with the St. Jude protocols experienced grade (+++) chemotherapeutic effects, and 22% of the patients treated before 1991 with regimen A<jats:sub>1<\/jats:sub>, or new A<jats:sub>1<\/jats:sub> of the Study Group of Japan showed grade (+++) effects, whereas 56% of the patients treated after 1991 with either regimen A<jats:sub>3<\/jats:sub> or <jats:sub>98<\/jats:sub>A<jats:sub>3<\/jats:sub> exhibited grade (+++) chemotherapeutic effects. Histologic chemotherapeutic effects were roughly parallel with a good prognosis. Pediatr Blood Cancer \u00a9 2005 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20345","type":"journal-article","created":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T06:17:20Z","timestamp":1117606640000},"page":"656-662","source":"Crossref","is-referenced-by-count":8,"title":["Histologic survey of neuroblastomas after intensive induction chemotherapy"],"prefix":"10.1002","volume":"45","author":[{"given":"Yoshiaki","family":"Tsuchida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Kuroiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiji","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,5,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/jpsu.2002.36187"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2003.11.028"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpedsurg.2004.02.041"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-36952"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.191"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19901101)66:9<1879::AID-CNCR2820660905>3.0.CO;2-L"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199807)31:1<1::AID-MPO1>3.0.CO;2-H"},{"key":"e_1_2_6_9_2","first-page":"453","volume-title":"Neuroblastoma","author":"Tsuchida Y","year":"2000"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174879"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811115)48:10<2310::AID-CNCR2820481029>3.0.CO;2-W"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811015)48:8<1715::AID-CNCR2820480805>3.0.CO;2-Y"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3468(97)90467-X"},{"key":"e_1_2_6_14_2","first-page":"1","volume-title":"Peripheral neuroblastic tumors and pheochromocytoma, Histological Classification and Color Atlas of Tumors in Infancy and Childhood II","author":"The Japanese Society of Pathology, The Committee on Histological Classification of Childhood Tumors","year":"2004"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3468(92)90195-D"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3468(95)90576-6"},{"key":"e_1_2_6_17_2","first-page":"497","volume-title":"Neuroblastoma","author":"Tsuchida Y","year":"2000"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02306083"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20345","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,8]],"date-time":"2023-10-08T19:57:11Z","timestamp":1696795031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,31]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,10,15]]}},"alternative-id":["10.1002\/pbc.20345"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20345","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,31]]}}}